The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
MANIFEST-2 trial update: Significant improvement in SVR35 and TSS50
On November 21, 2023, topline results were released from the phase III MANIFEST-2 trial (NCT04603495) investigating pelabresib, a bromodomain and extra-terminal domain inhibitor, in combination with ruxolitinib vs placebo for Janus kinase inhibitor-naïve patients with myelofibrosis.
The study met its primary endpoint of spleen volume reduction ≥35% (SVR35) at Week 24 for patients treated with combination therapy. Significant improvements in secondary endpoints were also observed, including change in Total Symptom Score (TSS) and ≥50% reduction in TSS at Week 24 in both intermediate-risk patients (90% of cohort) and the overall patient cohort.
To learn more about current combination therapies for Janus kinase inhibitor-naïve patients with myelofibrosis, read our recent MPN Hub article.
Results1
- Treatment with combination therapy showed a statistically significant improvement in SVR35 at Week 24
- In patients on combination therapy compared with patients on a placebo, SVR35 was achieved in 66% and 35%, respectively (p < 0.001).
- Combination therapy showed a favorable absolute change in TSS compared with placebo for both patients with intermediate-risk disease and the overall patient cohort (Figure 1).
Figure 1. Absolute TSS change in patients with intermediate-risk disease and the overall patient cohort*
TSS, Total Symptom Score.
*Adapted from MorphoSys.1
Combination therapy was also favorable in ≥50% reduction in TSS for both intermediate-risk patients and the overall patient cohort compared with placebo (Figure 2).
Figure 2. TSS50 in patients with intermediate-risk disease and the overall patient cohort*
TSS50, ≥50% reduction in Total Symptom Score.
*Adapted from MorphoSys.1
- The safety profile was consistent with previous reports, and no new safety signals were observed
- Anemia-related adverse events were reported less frequently in patients treated with combination therapy vs placebo
- More detailed results are due to be presented at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content